BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 10914724)

  • 1. INK4a gene expression and methylation in primary breast cancer: overexpression of p16INK4a messenger RNA is a marker of poor prognosis.
    Hui R; Macmillan RD; Kenny FS; Musgrove EA; Blamey RW; Nicholson RI; Robertson JF; Sutherland RL
    Clin Cancer Res; 2000 Jul; 6(7):2777-87. PubMed ID: 10914724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of p16INK4a/p16alpha and p19ARF/p16beta is frequently altered in non-small cell lung cancer and correlates with p53 overexpression.
    Vonlanthen S; Heighway J; Tschan MP; Borner MM; Altermatt HJ; Kappeler A; Tobler A; Fey MF; Thatcher N; Yarbrough WG; Betticher DC
    Oncogene; 1998 Nov; 17(21):2779-85. PubMed ID: 9840942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival.
    Hui R; Ball JR; Macmillan RD; Kenny FS; Prall OW; Campbell DH; Cornish AL; McClelland RA; Daly RJ; Forbes JF; Blamey RW; Musgrove EA; Robertson JF; Nicholson RI; Sutherland RL
    Oncogene; 1998 Aug; 17(8):1053-9. PubMed ID: 9747885
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of cyclin D1 messenger RNA predicts for poor prognosis in estrogen receptor-positive breast cancer.
    Kenny FS; Hui R; Musgrove EA; Gee JM; Blamey RW; Nicholson RI; Sutherland RL; Robertson JF
    Clin Cancer Res; 1999 Aug; 5(8):2069-76. PubMed ID: 10473088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclin DI amplification is not associated with reduced overall survival in primary breast cancer but may predict early relapse in patients with features of good prognosis.
    Seshadri R; Lee CS; Hui R; McCaul K; Horsfall DJ; Sutherland RL
    Clin Cancer Res; 1996 Jul; 2(7):1177-84. PubMed ID: 9816285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic and epigenetic alterations of the cyclin-dependent kinase inhibitors p15INK4b and p16INK4a in human thyroid carcinoma cell lines and primary thyroid carcinomas.
    Elisei R; Shiohara M; Koeffler HP; Fagin JA
    Cancer; 1998 Nov; 83(10):2185-93. PubMed ID: 9827724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypomethylation and increased gene expression of p16INK4a in primary and metastatic breast carcinoma as compared to normal breast tissue.
    Van Zee KJ; Calvano JE; Bisogna M
    Oncogene; 1998 May; 16(21):2723-7. PubMed ID: 9652738
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential loss of expression of p16(INK4a) rather than p19(ARF) in breast cancer.
    Brenner AJ; Paladugu A; Wang H; Olopade OI; Dreyling MH; Aldaz CM
    Clin Cancer Res; 1996 Dec; 2(12):1993-8. PubMed ID: 9816158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic value of p16INK4a and p14ARF gene hypermethylation in human colon cancer.
    Lee M; Sup Han W; Kyoung Kim O; Hee Sung S; Sun Cho M; Lee SN; Koo H
    Pathol Res Pract; 2006; 202(6):415-24. PubMed ID: 16675157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin D1 expression is associated with poor prognostic features in estrogen receptor positive breast cancer.
    Aaltonen K; Amini RM; Landberg G; Eerola H; Aittomäki K; Heikkilä P; Nevanlinna H; Blomqvist C
    Breast Cancer Res Treat; 2009 Jan; 113(1):75-82. PubMed ID: 18240019
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cyclin D1 and estrogen receptor messenger RNA levels are positively correlated in primary breast cancer.
    Hui R; Cornish AL; McClelland RA; Robertson JF; Blamey RW; Musgrove EA; Nicholson RI; Sutherland RL
    Clin Cancer Res; 1996 Jun; 2(6):923-8. PubMed ID: 9816251
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cyclin D1 and p16INK4A expression predict reduced survival in carcinoma of the anterior tongue.
    Bova RJ; Quinn DI; Nankervis JS; Cole IE; Sheridan BF; Jensen MJ; Morgan GJ; Hughes CJ; Sutherland RL
    Clin Cancer Res; 1999 Oct; 5(10):2810-9. PubMed ID: 10537346
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Relationship between alterations of p16INK4a and p14ARF genes of CDKN2A locus and gastric carcinogenesis].
    Tang SH; Yang DH; Luo HS; Yu JP; Shu JC
    Zhonghua Liu Xing Bing Xue Za Zhi; 2004 Jun; 25(6):517-21. PubMed ID: 15231134
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mechanisms of p16INK4A inactivation in non small-cell lung cancers.
    Gazzeri S; Gouyer V; Vour'ch C; Brambilla C; Brambilla E
    Oncogene; 1998 Jan; 16(4):497-504. PubMed ID: 9484839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers.
    Takahashi Y; Miyoshi Y; Takahata C; Irahara N; Taguchi T; Tamaki Y; Noguchi S
    Clin Cancer Res; 2005 Feb; 11(4):1380-5. PubMed ID: 15746036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The inhibitor of cyclin-dependent kinase 4a/alternative reading frame (INK4a/ARF) locus encoded proteins p16INK4a and p19ARF repress cyclin D1 transcription through distinct cis elements.
    D'Amico M; Wu K; Fu M; Rao M; Albanese C; Russell RG; Lian H; Bregman D; White MA; Pestell RG
    Cancer Res; 2004 Jun; 64(12):4122-30. PubMed ID: 15205322
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Methylation and messenger RNA expression of p15INK4b but not p16INK4a are independent risk factors for ovarian cancer.
    Liu Z; Wang LE; Wang L; Lu KH; Mills GB; Bondy ML; Wei Q
    Clin Cancer Res; 2005 Jul; 11(13):4968-76. PubMed ID: 16000597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relationship between alterations of p16(INK4a) and p14(ARF) genes of CDKN2A locus and gastric carcinogenesis.
    Tang S; Luo H; Yu J; Yang D; Shu J
    Chin Med J (Engl); 2003 Jul; 116(7):1083-7. PubMed ID: 12890389
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elevated levels of chemokine receptor CXCR4 in HER-2 negative breast cancer specimens predict recurrence.
    Holm NT; Byrnes K; Li BD; Turnage RH; Abreo F; Mathis JM; Chu QD
    J Surg Res; 2007 Jul; 141(1):53-9. PubMed ID: 17574038
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.